-
Add to Cart The item has been addedAb176598-100μgNavicixizumab (anti-DLL4) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab (anti-DLL4) can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab (anti-DLL4) can be used in the research of ovarian, primary -
Add to Cart The item has been addedAb176598-10mgNavicixizumab (anti-DLL4) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab (anti-DLL4) can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab (anti-DLL4) can be used in the research of ovarian, primary -
Add to Cart The item has been addedAb176598-1mgNavicixizumab (anti-DLL4) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab (anti-DLL4) can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab (anti-DLL4) can be used in the research of ovarian, primary -
Add to Cart The item has been addedAb176598-5mgNavicixizumab (anti-DLL4) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab (anti-DLL4) can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab (anti-DLL4) can be used in the research of ovarian, primary -
Add to Cart The item has been addedAb170536-100μgNesvacumab (anti-ANGPT2) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1.Purity>95% -
Add to Cart The item has been addedAb170544-100μgNipocalimab (anti-FcRn) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 -
Add to Cart The item has been addedAb170277-100μgOfatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb170277-10mgOfatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb170277-1mgOfatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb170277-5mgOfatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb176458-100μgOlaratumab (anti-PDGFRA) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb176458-10mgOlaratumab (anti-PDGFRA) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
